1. Comparison of Timed Automata with Discrete Event Simulation for Modeling of Biomarker-Based Treatment Decisions: An Illustration for Metastatic Castration- Resistant Prostate Cancer 
Koen Degeling, MSc, Stefano Schivo, PhD, Niven Mehra, MD, PhD, Hendrik Koffijberg, PhD, Rom Langerak, PhD, Johann S. de Bono, MD, PhD, Maarten J. IJzerman, PhD 
Value in Health 
DOI: /j.jval
Copyright © 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

2. Fig. 1
Model structures. (A) Schematic overview of the mCRPC treatment process on which the DES model is based. (B) Schematic overview of the interactions on which the TA model is based. DES, discrete event simulation; mCRPC, metastatic castration-resistant prostate cancer; TA, timed automata.
Value in Health DOI: ( /j.jval )
Copyright © 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

3. Fig. 2
Incremental cost-effectiveness plot. The cost-effectiveness of the experimental strategy was compared with that of the control strategy at a willingness to pay of €50,000/QALY for both modeling methods. QALY, quality-adjusted life-year.
Value in Health DOI: ( /j.jval )
Copyright © 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

4. Fig. 3
Tornado plot showing the impact of the input parameters on the cost-effectiveness expressed as the net monetary benefit. The parameter values used for this analysis can be found in Table 1. CTC, circulating tumor cell; PSA, prostate-specific antigen; QOL, quality of life.
Value in Health DOI: ( /j.jval )
Copyright © 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions